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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To assess the accuracy of the four-symptom screen (cough, fever, night sweats, or weight loss) for identifying active TB in pregnant
PLHIV who are screened in an outpatient or community setting.
• To investigate potential sources of heterogeneity of the accuracy of the four-symptom screen between studies including: ART
status, CD4 cell count, gestational age, pregnancy stage (pregnancy vs. postpartum), screening test definition of cough (any cough vs.
cough greater than 2 weeks).
• To describe the accuracy of single symptoms included within the four-symptom screen, additional symptoms or symptom
combinations, for identifying active TB in pregnant PLHIV. For example, additional symptoms may include failure to gain weight or
fatigue.
B A C K G R O U N D
Tuberculosis (TB) is the leading cause of mortality in people living
with HIV (PLHIV) (UNAIDS 2016); and the third leading cause
of death among women of child-bearing age in high TB burden
areas (Mathad 2012). Every year, over 200,000 pregnant women
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are estimated to develop TB during pregnancy (Sugarman 2014),
though this is likely an underestimation due to administrative,
diagnostic, or possible immunologic-related delays in diagnosis
(Llewelyn 2000; Zenner 2012). Earlier detection and treatment of
TB in pregnant PLHIV is crucial in improving outcomes for both
mothers and their young children (Getahun 2012). The World
Health Organization (WHO) recommends that PLHIV, includ-
ing pregnant women, should be routinely screened for symptoms
of active TB at every health facility visit using a four-symptom
screen (cough, fever, night sweats, and weight loss (WHO 2011a).
Routine TB screening in settings of high HIV and TB burden of-
fers opportunity to identify PLHIV who require further diagnos-
tic work-up to evaluate for active TB, as well as PLHIV without
symptoms who are unlikely to have TB and may be candidates for
isoniazid preventive therapy (IPT) (WHO 2011a). Recent data
suggest that the performance of the four-symptom screen for ac-
tive TB may perform differently in pregnant PLHIV compared to
PLHIV in general (Hoffmann 2013; Kancheya 2014; LaCourse
2016; Modi 2016). For this systematic review, we will review the
accuracy of symptom screening in pregnant PLHIV for active TB.
Target condition being diagnosed
TB is an airborne infectious disease caused by organismswithin the
complex Mycobacterium tuberculosis (Mtb) (Pai 2016). Although
typically a disease of the lungs, Mtb can disseminate throughout
the body. Infection primarily occurs after close and prolonged ex-
posure to a person with active TB, with Mtb spread often occur-
ring through coughing. The majority of people infected withMtb
will not develop active TB and are often described as having la-
tent TB infection (LTBI). They are largely asymptomatic and not
infectious. Although previous descriptions have categorized LTBI
and active TB as binary states, in reality there is likely a spec-
trum: from clearance of the infection with evidence of immune
response, to LTBI and granuloma formation, to subclinical disease
(typically without symptoms but potentially infectious), to active
(symptomatic) disease (Lawn 2011). Active TB can occur after
recent exposure and infection, or much later in the setting of pro-
gression of previously quiescent LTBI. Approximately 5% to 15%
of people will develop active TB in the setting of recent infection
(within a few months or years), with the remaining described as
having LTBI who are then at risk of developing TB in the future
(Pai 2016).
Progression to active TB ismore likely to occur in the setting of im-
mune suppression with HIV or malnutrition (Horsburgh 2011).
HIV significantly increases the risk for progression from LTBI to
active TB (Lawn 2011), from an approximately 10% lifetime risk
to over 10% per year (Corbett 2003). Given this elevated risk of
active TB, the WHO recommends that PLHIV in TB-endemic
areas be provided IPT to reduce the risk of progression from LTBI
to active TB (WHO 2011a). The risk of active TB also appears to
be elevated in pregnant and postpartum women (Zenner 2012).
The time from LTBI to active TB (when it occurs) can be vari-
able, and it can take months to years for individuals to develop
symptoms and bacteriologically detectable TB. People with active
TB who are not on treatment can continue to be infectious for
prolonged periods of time. Untreated maternal active TB is asso-
ciated with poor maternal and infant outcomes (Getahun 2012;
Mathad 2012). TB diagnosis may be delayed in pregnant women
in part due to masking of symptoms from physiologic (Hamadeh
1992) or immunologic changes (Kourtis 2014; Mathad 2012;
Singh 2007) associated with pregnancy. Maternal HIV and TB
co-disease is associated with adverse infant outcomes including
prematurity, small for gestational age, vertical HIV transmission,
neonatal TB, and death (Getahun 2012; Mathad 2012). Treat-
ment for TB diagnosed during pregnancy should not be delayed
(Nahid 2016; WHO 2010). In a recent large case-control study
in South Africa, mothers with HIV and TB were more likely to
experience poor maternal and infant outcomes despite widespread
access to antiretroviral therapy (ART), TB treatment and infant
IPT (Salazar-Austin 2017).
TB symptom screening for PLHIV
The WHO defines screening for TB as the “systematic identifica-
tion of people with suspected active TB, in a predetermined target
group, using tests, examinations or other procedures that can be
applied rapidly” with the goal to “efficiently distinguish people
with a high probability of having active TB from those who are
unlikely to have active TB” (WHO 2013). Screening tests are not
intended to be diagnostic, rather after a positive screen result, di-
agnosis is established using additional diagnostic tests. Systematic
screening for TB is primarily provider-initiated, and allows for ear-
lier detection of TB and permits earlier treatment and improved
outcomes (WHO 2013). In contrast, “passive-case finding” often
relies on people with potential TB reporting their symptoms to
providers prior to further work-up.
As part of the guidelines for intensified TB case finding and iso-
niazid preventive therapy (IPT) for PLHIV in resource-limited
settings, the WHO recommends that PLHIV should be rou-
tinely screened for active TB at every health facility visit using a
four-symptom screen (cough, fever, night sweats, and weight loss:
CFSW) (WHO 2011a). The presence of any one of these four
symptoms is considered a positive screen. The absence of all four
symptoms is considered a negative screen. The goal of TB symp-
tom screening in PLHIV is two-fold: 1) to identify those with a
positive symptom screen who should undergo further evaluation
for active TB; and 2) to identify those with a negative symptom
screen who are unlikely to have TB and therefore should be offered
IPT. The recommendation regarding the use of the TB four-symp-
tom screen in PLHIV is based primarily on the individual partic-
ipant data meta-analysis performed by Getahun and colleagues of
12 observational studies including 8148 PLHIV (Getahun 2011).
The focus of that meta-analysis was to identify a combination
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of clinical symptoms that could be readily identified at any level
of health system with the combination of greatest sensitivity and
specificity, as well as negative predictive value, for active TB among
PLHIV. The best performing rule included the presence of any
one of CFSW with a sensitivity of 78.9% (95% CI 58.3% to
90.9%) and specificity of 49.6% (95%CI 29.2% to 70.1%). Neg-
ative predictive values were 99.6% (95%CI 99.5% to 99.6%) and
97.7% (95% CI 97.4% to 98.0%) for prevalences of 1% and 5%,
respectively.
TB symptom screening for pregnant PLHIV
Integrating TB case-finding within maternal and child health set-
tings is considered a fundamental part of the Global Plan to End
TB 2016-2020 (Stop TB Partnership 2015). The WHO guide-
lines specifically include TB screening of pregnant PLHIV using
the four-symptom screen (WHO 2011a). However, a number of
recently published studies report that the four-symptom screen ap-
pears to have lower sensitivity amongpregnant PLHIV (Hoffmann
2013; Kancheya 2014; LaCourse 2016; Modi 2016), compared
to PLHIV in general. Previously published estimates of the high
negative predictive value in pregnant PLHIV (Gupta 2011), may
be different in the current era of widespread ART (Ahmad Khan
2014; Rangaka 2012), including ART initiated for prevention of
mother-to-child transmission (PMTCT) of HIV in pregnant and
breastfeeding women and continued for life regardless of CD4
count (referred to as “Option B+” by the WHO) (WHO 2015a).
Index test(s)
The primary index test that we will evaluate in this review is the
WHO-recommended TB four-symptom screen, which consists of
questions regarding the presence of any cough (of any duration),
fever, night sweats, or weight loss (CFSW) to identify pregnant
PLHIV with active TB. The four-symptom screen consists of “Yes
or No” type questions regarding the presence of any CFSW symp-
toms. The presence of any one of these symptoms is considered a
positive screen. The absence of all four of these symptoms is con-
sidered a negative screen. The four-symptom screen is designed to
be easily asked by healthcare providers in an outpatient or commu-
nity setting and can be done efficiently in low-resource settings,
allowing for further diagnostics to be reserved for those individuals
who are most likely to have TB.
Clinical pathway
The four-symptom screen is the initial test for PLHIV in a clini-
cal pathway that includes subsequent confirmatory testing (Xpert
MTB/RIF (Xpert), and in some cases chest radiograph or my-
cobacterial culture (solid or liquid)), to establish the diagnosis of
active TB (Figure 1) (WHO 2011a; WHO 2013). PLHIV with
a negative four-symptom screen are considered to be unlikely to
have TB, and are assessed for IPT eligibility to prevent active TB
(WHO 2011a; WHO 2013). PLHIV with a positive four-symp-
tom screen continue through a testing pathway and undergo fur-
ther diagnostic tests for TB and other diseases. The WHO cur-
rently recommends that PLHIV with a positive screen have an
Xpert (rapid nucleic acid amplification test forMtb), performedon
expectorated sputum as a primary diagnostic test for TB (WHO
2011b). If Xpert positive, individuals should be started on multi-
drug anti-tuberculosis treatment. In some settings, a culture is per-
formed if Xpert positive to confirm TB diagnosis or to confirm
whether the Mtb is sensitive to first-line anti-tuberculosis treat-
ment. Inmost resource-limited settings, routine confirmatory cul-
ture is not performed unless the patient has failed first-line therapy
or had a relapse. When available, chest radiography can also be
used as an additional screening test to improve the pretest prob-
ability of the subsequent diagnostic test, and to reduce the num-
ber of people who need to undergo further diagnostic evaluation
(WHO 2013). However in many settings, chest radiograph is un-
available (Saito 2012), therefore the WHO does not recommend
that it be required in the evaluation of individuals suspected of
TB. Additionally, clinicians may be reluctant to perform a chest
radiograph in pregnancy, despite the low risk of this amount of
radiation exposure to a pregnant woman or her fetus (Ratnapalan
2004).
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Figure 1. Algorithm for TB screening in adults and adolescents living with HIV in HIV-prevalent and
resource-constrained settings. Reprinted from: Guidelines for intensified tuberculosis case-finding and isoniazid
preventive therapy for people living with HIV in resource-constrained settings. Copyright: WHO 2011a.
Role of index test(s)
The role of the four-symptom screen is a triage test as part of an
algorithm to identify PLHIV who require further investigations
for TB (those with positive symptom screens), as well as those who
should be assessed for IPT (those with negative symptom screens)
(Figure 1). Triage tests are used before diagnostic tests with only
those patients with a positive result continuing through a testing
pathway (Bossuyt 2006). Triage tests may be less accurate than
existing diagnostics tests and are not meant to replace them, but
may have additional advantages such as ease of use or low cost.
A true positive (TP) on the four-symptom TB screen allows for
referral for further diagnostics leading to early diagnosis and treat-
ment of active TB. A true negative (TN) allows for potentially
costly diagnostics to be avoided, and for evaluation of IPT for
those truly without TB. The consequences of false positives (FP)
are further diagnostics with which active TB would be ruled out.
The consequences of false negatives (FN) are a possible delay in
diagnosis and treatment for active TB as well as the potential for
the inappropriate initiation of IPT. Individuals with active TB
who receive isoniazid as opposed to multi-drug anti-tuberculosis
therapy could be at risk of developing drug-resistant TB. However
rates of isoniazid resistance among PLHIV receiving IPT in TB
prevention trials are similar to baseline rates of isoniazid resistance,
and this risk is thought to be relatively low (WHO 2015c).
Alternative test(s)
The four-symptom screen is considered the standard of care for
the initial TB screening test for PLHIV (WHO 2011a). Alterna-
tive approaches to screening include passive case-finding, alternate
symptom screening, sputum microscopy, chest radiograph, and
urine lateral flow lipoarabinomannan (LAM) assay (LF-LAM).
Passive-case finding relies on identifying TB among people who
actively seek care for TB (WHO 2013). This is effective in iden-
tifying people who are highly symptomatic, but is less effective
in identifying people who may have less pronounced or protean
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symptoms which may often be the case in PLHIV.
Alternate symptom screening includes the presence of chronic
cough (for example longer than two weeks). Chronic cough has
low sensitivity for TB among PLHIV, leading to missed cases and
diagnostic delays (Getahun 2011).
Similarly, sputum microscopy has poor sensitivity in PLHIV, who
often have paucibacillary disease. Chest radiographs can be neg-
ative or inconclusive in PLHIV, and require expert trained staff
to read the images. Therefore the WHO does not recommend or
require the use of sputum microscopy or chest radiograph for the
initial screening test for TB in PLHIV (WHO 2011a).
LAM antigen is a lipopolysaccharide present in mycobacterial cell
walls, and can be detected in the urine of people with active TB
using urine LF-LAM (Lawn 2012). Urine-based testing has poten-
tial advantages over sputum-based testing due to ease of collection
and lower infection control risks compared to sputum collection.
However, due to low sensitivity and specificity (Shah 2016), the
WHO strongly recommends against using urine LF-LAM for TB
screening in PLHIV in general, except for those PLHIV with low
CD4 or who are seriously ill (WHO 2015b). Portable digital chest
radiographs with computer-assisted diagnosis, and non-sputum
based biomarkers may have a role for initial screening in the fu-
ture, but are not currently recommended in the initial screening
or triage for TB in PLHIV (UNITAID 2015).
Rationale
The aim of this systematic review is to synthesize evidence regard-
ing the accuracy of the four-symptom screen for active TB in preg-
nant PLHIV.
This subject is particularly relevant as identifying PLHIV with TB
to initiate timely TB treatment, and identifying PLHIV who are
safe to initiate IPT, are cornerstones of key strategies of the Global
Plan to End TB 2016-2020 (Stop TB Partnership 2015). The
Maternal-Child Tuberculosis Working Group of the International
Union Against Tuberculosis and Lung Disease has identified the
performance of TB screening tools in pregnant PLHIV as an im-
portant research gap (Modi 2017 [pers comm]).
This review will focus on pregnant PLHIV for a number of rea-
sons. The risk of TB in women, especially those with HIV, appears
higher during pregnancy and postpartum periods (Deluca 2009;
Hoffmann 2013; Kancheya 2014; LaCourse 2016; Modi 2016).
Maternal TB is associated with poor maternal and infant out-
comes, particularly among HIV-infected women and their chil-
dren (Getahun 2012:Mathad 2012; Salazar-Austin 2017). Timely
detection of TB in peripartum PLHIV may reduce TB-associated
morbidity and mortality. Antenatal and PMTCT settings provide
opportunity for routine TB symptom screening in pregnant PL-
HIV (Deluca 2009; Getahun 2012).
O B J E C T I V E S
To assess the accuracy of the four-symptom screen (cough, fever,
night sweats, or weight loss) for identifying active TB in pregnant
PLHIV who are screened in an outpatient or community setting.
Secondary objectives
• To investigate potential sources of heterogeneity of the
accuracy of the four-symptom screen between studies including:
ART status, CD4 cell count, gestational age, pregnancy stage
(pregnancy vs. postpartum), screening test definition of cough
(any cough vs. cough greater than 2 weeks).
• To describe the accuracy of single symptoms included
within the four-symptom screen, additional symptoms or
symptom combinations, for identifying active TB in pregnant
PLHIV. For example, additional symptoms may include failure
to gain weight or fatigue.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional and cohort studies in which preg-
nant PLHIV are tested with both TB symptom screening as well
as at least one of the reference standards (Xpert or culture). In ad-
dition, we will include diagnostic case control studies. Case con-
trol studies may overestimate sensitivity and specificity (Lijmer
1999); however, as we anticipate identifying few relevant studies,
we will include them. We will also include randomized controlled
trials with each arm as a separate study. In addition, we will in-
clude published TB prevalence surveys; however we will exclude
participants with known prevalent TB (i.e. on anti-tuberculosis
treatment at time of screening). Data from baseline measurement
in longitudinal cohorts, as well as interventional trials in which
persons with TB need to be excluded, will be eligible. For longitu-
dinal studies where incident TB is identified after enrolment, data
regarding symptom screening which occurs at the time of incident
TB diagnosis will be eligible.
We will focus on studies that clearly describe TB symptom screen-
ing in pregnant PLHIV either in their methods or results. We will
include studies that report data from which we can extract true
positives (TP), false positives (FP), false negatives (FN), and true
negatives (TN) for the four-symptom screen. Studies with zero
TB cases will be eligible for inclusion for estimates of specificity.
Studies in which not all participants undergo the reference stan-
dard will be eligible for inclusion, as long as it is clear which par-
ticipants underwent the index (symptom screening) and reference
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tests (Xpert or culture). Studies that screened PLHIV or pregnant
women in general but included pregnant PLHIV will be eligible,
as long as data can be extracted from the study specifically for
pregnant PLHIV.
Participants
Wewill include pregnant PLHIV of all ages eligible for TB screen-
ing and not yet known to have TB at time of screening, who were
screened in the outpatient or community setting. This may in-
clude pregnant PLHIV from all types of populations including the
general population of PLHIV (included in mass case finding in
TB prevalence surveys) as well as specifically targeted populations
(screening of household members of known TB cases).
Index tests
For the primary analyses, we will include studies which use the
four-symptom screen (cough, fever, night sweats, weight loss:
CFSW). A positive index test is the presence of any one of the
four symptoms. A negative index test is the absence of all four of
these symptoms. For our secondary analyses, we will also include
studies which include additional symptoms (e.g. fatigue, failure
to gain weight), and symptom combinations for identifying active
TB.
Target conditions
The target condition is active TB.
Reference standards
Our primary reference standards will be sputum mycobacterial
culture (liquid or solid) and Xpert, where ‘TB’ is defined as a
positive culture for Mtb or a positive Xpert result, and ‘No TB’
is defined as a negative culture for Mtb or negative Xpert result
(or if both tests are performed, then both tests are negative). In
general, mycobacterial culture is considered the reference standard
by which other TB diagnostics are assessed. For the purposes of
this systematic review, mycobacterial culture will include both liq-
uid (automated reading of mycobacterial growth inhibitor tubes
(MGIT)) and solid medium (Löwenstein-Jensen (LJ)). MGIT is
thought to have increased sensitivity for identifying Mtb, but po-
tentially lower specificity due to higher rates of contamination
(Somoskovi 2000). Xpert is a WHO-endorsed nucleic acid am-
plification (NAAT) for the diagnosis of TB, and is the recom-
mended primary diagnostic test for PLHIV in resource-limited
settings (WHO 2011b). In a recent systematic review, Xpert has
a pooled sensitivity of 89% (95% Credible Interval (CrI) 85% to
92%) and pooled specificity of 99% (95% CrI 98% to 99%) as
an initial diagnostic test as measured against mycobacterial culture
as the reference standard, with slightly reduced pooled sensitivity
among PLHIV, 79% (95% CrI 70% to 86%) (Steingart 2014).
For the purpose of this review, participants withmycobacterial cul-
ture negative for Mtb, but positive for nontuberculous mycobac-
teria will also be considered to have ‘No TB’.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress).
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register; Central Register of Controlled Tri-
als (CENTRAL), published in the Cochrane Library; MEDLINE
(OVID); Embase (OVID); CINAHL (EBSCOHost); Science Ci-
tation Index-Expanded (Web of Science) and Scopus. We will
search the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/en/), andClinicalTrials.gov (https:/
/clinicaltrials.gov/ct2/home), for trials in progress, using ’tubercu-
losis’ and ’symptom screening’ as search terms.
Searching other resources
We will contact researchers and experts in the field to identify any
additional eligible studies. We will also check the references of all
included studies to identify additional studies.
Data collection and analysis
Selection of studies
Two review authors will independently screen all titles and ab-
stracts to determine potentially eligible studies. We will then ob-
tain the full-text articles of these potentially eligible studies and
two review authors will independently assess whether they should
be included based on pre-defined inclusion and exclusion criteria.
We will resolve disagreements by discussion between the two re-
view authors, as well as a third author if necessary. We will contact
study authors for clarification of methods and other information if
necessary. Reasons for exclusion will be recorded and summarized
in a ‘Characteristics of excluded studies’ table. We will illustrate
the study selection process in a PRISMA diagram.
Data extraction and management
Wehave drafted a data extraction form (Appendix 2) and will pilot
the form with at least two included studies. We will finalize the
form based on this pilot. Two review authors will independently
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extract data from each study using the finalized form. Both re-
view authors will discuss any inconsistencies to obtain consensus.
Any disagreements will be resolved either through consensus or
by a third review author if necessary. We will enter into a database
(either Excel or Research Electronic Data Capture [REDCap])
(Harris 2009). Extracted datawill be stored on password-protected
computers, or in the case of REDCap (www.iths.org/investigators/
services/bmi/redcap/), in a password protected online web appli-
cation. Extracted data will be stored for review updates and we
will seek Cochrane and CDC approval prior to update.
Data extraction will include the following characteristics.
• Authors, title, publication year, journal, email address of
corresponding author.
• Whether author contacted, dates of contact, author
response.
• Year(s) study conducted.
• Language of the publication, publication status.
• Country where study conducted.
• Reference standard(s): sputum Xpert, culture (solid or
liquid), number of samples per individual.
• Whether participants unable to produce sputum included
in study.
• Clinical setting (outpatient, community screening),
participant selection.
• Study design (including direction of study data collection
i.e. prospective, retrospective).
• Index test(s): four-symptom screen (CFSW), additional
symptoms (cough > 2 weeks, failure to gain weight, fatigue, etc.).
• Purpose of screening as described in the study.
• Number after screening by study inclusion and exclusion
criteria.
• Number included in analysis (include if available # in study,
# pregnant PLHIV, # screened - # withdrew).
• Patient characteristics: age (range, mean (SD), median
(IQR));
• HIV characteristics: HIV status of participants (#, %), ART
status (combination ART vs. ART for PMTCT alone), CD4
(range, mean (SD), median (IQR)), HIV viral load (VL) (%
with undetectable VL, range, mean (SD), median (IQR)).
• Pregnancy characteristics: gestational age (range, mean
(SD), median (IQR)), postpartum age (range, mean (SD),
median (IQR)), pregnancy vs. postpartum.
• Patients with a previous history TB (#, %).
• Details of outcomes: # of true positives (TP), true negatives
(TN), false positives (FP), false negatives (FN); # participants
with missing and/or unavailable results.
We will classify country income status as ‘low and middle income’
or ‘high income’, according to the World Bank List of Economies
(World Bank 2016). Additional tables may be created for other
symptoms or symptom combinations if they are reported. Review
authors who are also authors of primary studies will recuse them-
selves from the screening and data extraction of their own studies
and an alternate reviewer will perform the screening and data ex-
traction.
Assessment of methodological quality
We will assess the methodological quality of included studies
using the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) instrument (Whiting 2011), which we will tailor
to this review. The QUADAS-2 consists of four domains: (1) pa-
tient selection; (2) index test(s); (3) reference standard(s); and (4)
flow and timing. We will assess all domains for risk of bias and the
first three domains for concerns regarding applicability. As recom-
mended, we will first develop guidance on how to appraise each
question and interpret this information. Then, one review author
will pilot the tool with two of the included studies. Based on expe-
rience gained from the pilot, we will finalize the tool. Two review
authors will independently complete QUADAS-2.Wewill resolve
disagreements through discussion or, failing that, arbitration by a
third review author. We will present the results of the quality as-
sessment in the text, table, and graphs. The preliminary tool with
signalling questions tailored to this review is in Appendix 3.
Statistical analysis and data synthesis
We will perform descriptive analyses of the characteristics of the
included studies using Stata 14 (StataCorp 2015), and present key
study characteristics in ‘Characteristics of included studies’ tables.
We will use data reported in the two-by-two tables to calculate
sensitivity and specificity estimates and 95% confidence intervals
(CI) for the accuracy of the four-symptom screen from individual
studies using Review Manager 5 (RevMan 5) (RevMan 2014).
When possible, TB cases diagnosed by CXR or clinical suspicion
alone will be excluded from the extracted data. We will present
individual study results graphically by plotting the estimates of
sensitivity and specificity (and their 95% CIs) in forest plots and
receiver operating characteristic (ROC) space using RevMan 5. If
data allow, we will include descriptive analyses of the performance
of single symptoms, additional symptoms, or different symptom
combinations other than the four-symptom screen.
We will fit a bivariate random-effects meta-analysis model (Chu
2010;Macaskill 2010; Reitsma 2005) to estimate the pooled sensi-
tivity and specificity and corresponding 95% CIs using the meqr-
logit and metandi commands in Stata (version 14). We have se-
lected the bivariate model because the four-symptom TB screen
uses a common positivity criteria or threshold, i.e. the presence of
any one of the four symptoms is considered a positive result. The
bivariate random-effects approach will allow us to calculate the
pooled estimates of sensitivity and specificity while dealing with
potential sources of variation caused by: (1) variability of sensi-
tivity and specificity estimates within individual studies; (2) cor-
relation between sensitivity and specificity across studies; and (3)
variation in sensitivity and specificity between studies. For some
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subgroups or screen definitions we may not be able to give mean-
ingful summary estimates of sensitivity and specificity, therefore
they will be evaluated using descriptive methods.
If we find that, in using hierarchical models, the analyses fail to
converge due to a small number of studies or sparse data, we will
consider simplifying the models into fixed-effect models by elim-
inating the random-effects parameters for sensitivity or specificity
(Takwoingi 2017).
Investigations of heterogeneity
We will examine the forest plots and ROC plots through visual
examination for heterogeneity. If the data allow, we will analyse
potential determinants or sources of heterogeneity as covariates in
the models using meta-regression (Macaskill 2010). We will in-
clude the following pre-specified categorical study-level covariates.
• ART status (on ART vs. not ART).
• Pregnancy stage (pregnant vs. postpartum).
• Screening test definition of cough (any cough vs. cough
longer than two weeks).
Sensitivity analyses
If there are sufficient data, we will perform sensitivity analyses to
explore the contribution of risk of bias and study characteristics
on accuracy of the four-symptom TB screen by including only
studies that meet the following criteria in the meta-analysis.
• Studies that avoided case-control design.
• Studies that avoided inappropriate exclusions.
• Studies that interpreted the result of symptom screen (index
test) without knowledge to the result of the reference standard.
• Studies where TB diagnosis is based solely on the reference
of Xpert or culture (e.g. studies did not use CXR or clinical
diagnosis as the basis for classifying patients as having “TB” or
“No TB”).
Assessment of reporting bias
We will not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for di-
agnostic test accuracy studies (Macaskill 2010).
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A P P E N D I C E S
Appendix 1. Search strategy
We will include search terms to capture clinical tuberculosis symptoms among HIV-infected pregnant women. We will utilize both
MeSH terms and free text terms to identify phrases of our search. In order to increase the sensitivity of our findings, we will search “All
fields” when possible rather than only title and abstracts. We will include the following search terms.
1 exp HIV Infections/
2 HIV/ or HIV-2/ or HIV-1/
3 (HIV or hiv-1* or hiv-2* or hiv1 or hiv2 or hiv-I* or hiv-II* or hivI* ).tiab
4 “HIV infect*”.tiab
5 (“human immunodeficiency virus” or “human immunedeficiency virus” or “human immuno-deficiency virus” or “human immune-
deficiency virus” or (human immun* and deficiency virus)).tiab
6 (“acquired immunodeficiency syndrome” or “acquired immunedeficiency syndrome” or AIDS).tiab
7 (“acquired immuno-deficiency syndrome” or “acquired immune-deficiency syndrome”).tiab
8 or/1-7
9 exp Tuberculosis/
10 (tuberculosis or TB or tuberculoses or tuberculous).tiab
11 Mycobacterium tuberculosis/
12 9 or 10 or 11
13 8 and 12
14 (pregnant adj3 wom?n).mp.
15 Pregnant Women/
16 Pregnancy/
17 pregnan*.tiab
18 14 or 15 or 16 or 17
19 13 and 18
20 mass screening.mp. or Mass Screening/
21 physical examination.mp. or Physical Examination/
22 Cough/
23 Weight Loss/
24 Fever/ or Fatigue/
25 Prenatal Diagnosis/ or ((prenatal* or pre natal* or antenatal* or ante natal*) adj2 screen*).tiab.
26 clinical algorith*.mp.
27 (cough* or “weight loss*” or “weight reduction*” or fever* or pyrexia* or “night sweat*” or fatigue*).tiab
28 (“four-symptom screen*” or “four-symptoms screen*”).tiab
29 triag*.mp. or Triage/
30 case finding.mp.
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31 symptom* adj2 screen* .mp.
32 or/20-31
33 19 and 32
This is the preliminary search strategy for MEDLINE. It will be adapted for other electronic databases. All search strategies will be
reported in full in the final version of the review.
Appendix 2. Data extraction form
Symptom screen for active tuberculosis in pregnant women living with HIV: data extraction form
Study ID
Name of data extractor 1 - SL 2 - JM 3 - Other (Specify )
First Author
Corresponding author and email
Was an author contacted? 1 - Yes Contact Date:
YES Response Result:
NO Response
2 - No
Title of study
Year of publication
Year(s) study conducted
Language 1 - English 2 - French 3 - Spanish
4 - Other:
Journal
Publication status of study 1 - Published
2 - Unpublished What is the anticipated study completion date?
Country or countries where study was conducted
(list all)
World Bank Classification 1 - Middle/Low 2 - High 3 - Study includes both middle/low & high
For the diagnosis of active TB, what reference stan-
dard was used to identify TB and not TB? Circle all
that apply
NAAT - nucleic acid amplification test
LJ - Lowenstein-Jensen
ZN - Ziehl-Neelsen stain
1 - Sputum: Solid Culture (circle method) LJ 7H10 7H11
2 - Sputum: Liquid Culture (circle method) MGIT Bactec460
3 - Sputum: Both Solid and Liquid Culture (specify above)
4 - Sputum: NAAT (circle method) GeneXpert Other (specify):
5 - Sputum: Smear (circle method) ZN FM
6 - Sputum: Other, specify:
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(Continued)
FM - Fluorescence microscopy 7 - Non-sputum: specify:
9 - Unknown/not reported
Were patients unable to produce sputa included in
this study?
1 - Yes
2 - No
9 - Unknown/not reported
How many sputum specimens per patient were ob-
tained for the diagnosis of active TB?
1 - One
2 - Two
3 - Other (specify):
9 - Unknown/not reported
What was the clinical setting of the study? 1 - Outpatient, Maternal/child health clinic
2 - Outpatient, HIV clinic or other general medicine clinic
3 - Inpatient
4 - Both out-patient and in-patient
5 - Community-based
6 - Other, describe:
9 - Unknown/not reported
Study design 1 - Randomized trial
2 - Cross-sectional
3 - Cohort
4 - Case-control
5 - Other (specify):
9 - Unknown/not reported
What was the manner of patient selection into the
study?
1 - Consecutive
2 - Random
3 - Convenience
4 - Other, specify
9 - Unclear/not reported
Direction of study data collection 1 - Prospective
2 - Retrospective
9 - Unknown/not reported
Comments about study design
Index tests: What symptoms were evaluated as
screens for TB? Indicate all that apply
1 - Cough
2 - Fever
3 - Night sweats
4 - Weight loss
5 - Cough > 2 week duration
6 - Failure to gain weight
7 - Other, specify:
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(Continued)
Please select the statement that best describes the
purpose of screening as described in the study
1- Pregnant PLHIV with signs or symptoms suggestive of active TB were
screened for TB only
2 - Pregnant PLHIV with and without TB signs or symptoms were screened
for TB
3 - Neither 1 nor 2.
4 - Other, specify:
Number after screening by exclusion & inclusion
criteria (Total for study) 9 - Unknown/not reported
Number included in analysis (# screened - # with-
drawals)
(Total for study)
9 - Unknown/not reported
HIV status of participants
(Total for study)
1 - HIV-positive
2 - Both HIV-positive and HIV-negative
9 - Unknown/not reported
Percentage of HIV-negative and HIV-positive % of participants were HIV-negative
% of participants were HIV-positive
Specify numerator/denominator
Pregnancy status of participants 1 - Pregnant
2 - Postpartum
3 - Pregnant and postpartum
9 - Unknown/not reported
Percentage of pregnant and postpartum % of participants were pregnant
% of participants were postpartum
Specify numerator/denominator
Gestational or Postpartum age Pregnant:
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not re-
ported
Postpartum:
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not reported
Percentage of pregnant and/or postpartum and
HIV-positive
% of participants were pregnant or postpartum, and HIV-positive
Specify numerator/denominator
Age of participants All Study Participants:
Range:
Mean (SD):
Median (IQR):
Pregnant PLHIV:
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not reported
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(Continued)
9 - Unknown/not re-
ported
Reported AFB-smear status All Study Participants:
% of participants
have AFB-smear posi-
tive pulmonary TB
Specify numerator/de-
nominator
9 - Unknown/not re-
ported
Pregnant PLHIV:
% of participants have AFB-smear positive pul-
monary TB
Specify numerator/denominator
9 - Unknown/not reported
Participant engagement in medical care (indicate all
that apply)
All Study Participants:
1 - Previously engaged
in HIV care
2 - Never before re-
ceived HIV care
3 - Both
4 - Other, specify:
9 - Unknown/not re-
ported
Pregnant PLHIV:
1 - Previously engaged in HIV care
2 - Never before received HIV care
3 - Both
4 - Other, specify:
9 - Unknown/not reported
Proportion of participants with HIV never before
engaged in care (i.e. enrolling into HIV care)
PLHIV:
% of participants
previously engaged in
care
% of participants
never before engaged in
care
Specify numerator/de-
nominator
9 - Unknown/not re-
ported
Pregnant PLHIV:
% of participants previously engaged in care
% of participants never before engaged in care
Specify numerator/denominator
9 - Unknown/not reported
ART status of PLHIV PLHIV:
1 - No ART
2 - Combined ART
3 - ART for PMTCT
only
9 - Unknown/not re-
ported
Pregnant PLHIV:
1 - No ART
2 - Combined ART
3 - ART for PMTCT only
9 - Unknown/not reported
Proportion of PLHIV participants receiving combi-
nation ART (i.e. not only treated for PMTCT)
% of participants were on no ART
% of participants were on combined ART
% of participants were on ART for PMTCT only
9 - Unknown/not reported
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(Continued)
What was the CD4-cell count of included patients? PLHIV:
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not re-
ported
Pregnant PLHIV:
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not reported
What was the HIV viral load of included patients? PLHIV:
%with unde-
tectable viral load
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not re-
ported
Pregnant PLHIV:
% with undetectable viral load
Range:
Mean (SD):
Median (IQR):
9 - Unknown/not reported
Did the study include patients with previous TB
history?
All Study Participants:
1 - Yes % of
participants had a prior
history of TB
Specify numerator/de-
nominator
2 - No
9 - Unknown/not re-
ported
Pregnant PLHIV:
1 - Yes % of participants had a prior history
of TB
Specify numerator/denominator
2 - No
9 - Unknown/not reported
WHO four-symptom
screen
Reference Test: Xpert or culture
TB Disease Not TB Total
Positive
Negative
Total
Pregnant PLHIV on
ART
Reference Test: Xpert or culture
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(Continued)
WHO four-symptom
screen
TB Disease Not TB Total
Positive
Negative
Total
Pregnant PLHIV not
on ART
Reference Test: Xpert or culture
WHO four-symptom
screen
TB Disease Not TB Total
Positive
Negative
Total
Symptom
(specify symptom):
Reference Test: Xpert or Culture
TB Disease Not TB Total
Positive
Negative
Total
Appendix 3. QUADAS-2
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled?
We will score ’yes’ if the study enrolled a consecutive or random sample of eligible participants (i.e., pregnant PLHIV); ’no’ if the study
selected participants by convenience; and ’unclear’ if the study did not report the manner of participant selection or we could not tell.
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Signalling question 2: Was a case-control design avoided?
Case control study design may overestimate sensitivity and specificity for screening and diagnostic tests (Lijmer 1999). We will score
’yes’ to studies which are not case-control studies. We will score ’no’ to studies which are case-control studies. We will score ’unclear’ if
we could not tell.
Signalling question 3: Did the study avoid inappropriate exclusions?
We will score ’yes’ to studies, which included: a) all pregnant PLHIV regardless of symptoms and b) pregnant PLHIV who were unable
to produce sputum (expectorated or induced). We will score ’no’ if studies excluded pregnant PLHIV on the basis of no symptoms
or the inability to produce sputum (no attempts at sputum induction). We will also score ’no’ if studies excluded pregnant PLHIV
presumed to have extrapulmonary TB. We will score ’unclear’ if we could not tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We are interested in how the four-symptom TB screen performs in pregnant PLHIV who would be screened in routine practice. We
have defined ’screening’ for active TB in accordance with WHO guidance, as “the systematic identification of people with suspected
active TB, in a predetermined target group, using tests, examinations or other procedures that can be applied rapidly”(WHO 2013).
We will score ’low concern’ for studies in which the four-symptom TB screen was performed uniformly within the predetermined
study target population of pregnant PLHIV, ’high concern’ if the four-symptom TB screen was not performed uniformly within the
predetermined study target population of pregnant PLHIV, and ’unclear concern’ if we could not tell.
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard?
We will score ’yes’ if the study interpreted the result of the four-symptom TB screen blinded to the result of the reference standard or
if it is clear that the results of the index test were available before the results of the reference standard were known; we will score ’no’
if the study did not interpret the result of the four-symptom TB screen blinded to the result of the reference standard. We will score
’unclear’ if we could not tell if the index test results were interpreted without knowledge of the reference standard results. We will also
answer yes if the tests (index test and reference standard) were carried out in different places.
Signalling question 2: if a threshold was used to define positivity, was it prespecified?
This question is not applicable for our review.
Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question?
If index test methods vary from those specified in the review question, concerns about applicability may exist. We will score ’high
concern’ if the four-symptom TB screen was applied for the purpose of TB diagnosis, rather than as a TB screening tool; ’low concern’
if the four-symptom TB screen was applied as a screening tool, and ’unclear concern’ if we could not tell.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
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Microbiological reference standard
Mycobacterial culture (liquid or solid) or nucleic acid amplification tests (e.g., Xpert) are considered the best reference standards to
identify active TB in PLHIV. Due to the difficulties in diagnosing HIV-associated TB, it is recommended that multiple cultures from
sputum be evaluated.
We will answer ’no’ if a consistent approach was not followed for all patients (for example, some but not all patients were asked to
provide sputum for Xpert or culture testing). We will answer ’unclear’ if we could not tell.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
We will answer ’yes’ if the study interpreted the result of the reference standard blinded to the result of the four-symptom TB screen, or
if the reference standard result was reported on an automated instrument; ’no’ if the study did not interpret the result of the reference
standard blinded to the result of the four-symptom TB screen, and ’unclear’ if we could not tell. We will also answer yes if the tests
carried out in different places.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
In general, we think there will be low concern for almost included studies based on the current definition of the reference standard.
We will judge ’high concern’ if the included studies did not speciate mycobacteria isolated in culture, ’low concern’ if speciation was
performed, and ’unclear’ if we could not tell.
Domain 4: Flow and timing
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and reference standard?
We will answer ’yes’ if the index test and reference standard(s) are collected on the same patients at the same time or within seven
days. We chose seven days as a time period during which either treatment of TB or natural progression of TB without treatment could
impact test results. We will answer ’no’ if specimens were collected for index and reference standard tests greater than seven days apart,
and ’unclear’ if we could not tell.
Signalling question 2: did all patients receive the same reference standard?
We will answer ’yes’ if all participants in the study received the same reference standard to confirm TB; ’no’ if not all patients received
the reference standard to confirm TB, and ’unclear’ if we could not tell.
Signalling question 3: were all patients included in the analysis?
We will determine the answer to this question by comparing the number of participants enrolled in the study with the number of
participants included in the two-by-two tables. We will answer ’yes’ if the number of participants in the two-by-two tables match the
number of participants recruited into the study, or if these numbers do not match, then sufficient explanation is provided for any
discrepancy. We will answer ’no’ if the number of participants in the two-by-two tables do not match the number of participants
recruited into the study and insufficient explanation is provided for any discrepancy, and ’unclear’ if we could not tell.
Judgments for overall ’Risk of bias’ assessments for domains
If we answer:
• all signalling questions for a domain “yes,” then we will judge risk of bias “low”;
• all or most signalling questions for a domain “no,” then we will judge risk of bias “high”;
• one signalling question for a domain “no,” we will discuss with a third author the ’Risk of bias’ judgement;
• all or most signalling questions for a domain “unclear,” then we will judge risk of bias “unclear”;
• only one signalling question for a domain “unclear,” we will discuss with a third author the ’Risk of bias’ judgement for the
domain.
19Symptom screening for active tuberculosis in pregnant women living with HIV (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
SL wrote the initial draft of the protocol. LC developed the search strategy. DH designed draft abstraction forms. EO drafted the data
analysis sections with input from SP and KRS. KRS drafted the QUADAS-2 section. KRS and SP contributed methodological advice.
All authors (EO, AB, DB, LC, DH, JM, SL, SM, KRS, and SP) provided input for the protocol.
D E C L A R A T I O N S O F I N T E R E S T
The review authors (EO, AB, DB, LC, DH, JM, SL, SM, KRS, SP) have no known conflicts of interest. LC, DH, SL, JM, and SM
have conducted primary research regarding evaluating symptom screening for TB in pregnant PLHIV.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Cystic Fibrosis Foundation (DH), USA.
• NIH/NIAID K23 Career Development Award (SL, DH), USA.
• NIH/NIAID R21 (DH), USA.
• University of Washington Center for AIDS Research (SL, DH), USA.
• University of Washington Strategic Analysis, Research & Training (START) Center (DB), USA.
• US President’s Emergency Plan for AIDS Relief through the US Centers for Disease Control and Prevention (SM, SP), USA.
• NIH/NIAID K23 (K23AI129854) Award (JM), USA.
• NIH/NICHD R01 (R01HD081929) Award (JM), USA.
• Department for International Development (DFID), UK.
Grant: 5242
20Symptom screening for active tuberculosis in pregnant women living with HIV (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
